Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers

Table 2

Comparison of baseline data (n = 44).

Items	STG	CTG	X^2/t
Gender			0.188	0.665
Male	27 (61.36%)	25 (56.82%)
Female	17 (38.64%)	19 (43.18%)
Average age (mean ± SD, years old)	64.38 ± 7.28	64.56 ± 7.24	0.116	0.908
BMI (mean ± SD, kg/m^2)	21.25 ± 1.26	21.32 ± 1.23	0.264	0.793
Pathological types
Adenocarcinoma	24 (54.55%)	26 (59.09%)	0.185	0.667
Squamous cell carcinoma	17 (38.64%)	14 (31.82%)	0.448	0.503
Others	3 (6.82%)	4 (9.09%)	0.155	0.694
Metastatic sites
Liver	12 (27.27%)	10 (22.73%)	0.246	0.620
Pleura	8 (18.18%)	11 (25.00%)	0.612	0.434
Lymph nodes	19 (43.18%)	16 (36.36%)	0.441	0.507
Bones	5 (11.36%)	7 (15.91%)	0.389	0.533
Smoking history			0.279	0.597
Yes	34 (77.27%)	36 (81.82%)
No	10 (22.73%)	8 (18.18%)
Drinking history			0.196	0.658
Yes	29 (65.91%)	27 (61.36%)
No	15 (34.09%)	17 (38.64%)
Marital status
Married	40 (90.91%)	39 (88.64%)	0.124	0.725
Unmarried	1 (2.27%)	3 (6.82%)	1.048	0.306
Divorced	3 (6.82%)	2 (4.55%)	0.212	0.645
Education level
University	6 (13.64%)	4 (9.09%)	0.451	0.502
Middle school	12 (27.27%)	16 (36.36%)	0.838	0.360
Primary school	26 (59.09%)	24 (54.55%)	0.185	0.667
Residence			0.049	0.826
Urban area	17 (38.64%)	16 (36.36%)
Rural area	27 (61.36%)	28 (63.64%)